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Abstract
The metabolism of hepcidin is profoundly modified in chronic kidney disease (CKD). We investigated its relation to iron
disorders, inflammation and hemoglobin (Hb) level in 199 non-dialyzed, non-transplanted patients with CKD stages 1–5. All
had their glomerular filtration rate measured by 51Cr-EDTA renal clearance (mGFR), as well as measurements of iron markers
including hepcidin and of erythropoietin (EPO). Hepcidin varied from 0.2 to 193 ng/mL. The median increased from 23.3 ng/
mL [8.8–28.7] to 36.1 ng/mL [14.1–92.3] when mGFR decreased from $60 to ,15 mL/min/1.73 m2 (p = 0.02). Patients with
absolute iron deficiency (transferrin saturation (TSAT),20% and ferritin,40 ng/mL) had the lowest hepcidin levels (5.0 ng/
mL [0.7–11.7]), and those with a normal iron profile (TSAT $20% and ferritin $40), the highest (34.5 ng/mL [23.7–51.6]). In
multivariate analysis, absolute iron deficiency was associated with lower hepcidin values, and inflammation combined with
a normal or functional iron profile with higher values, independent of other determinants of hepcidin concentration,
including EPO, mGFR, and albuminemia. The hepcidin level, although it rose overall when mGFR declined, collapsed in
patients with absolute iron deficiency. There was a significant interaction with iron status in the association between Hb and
hepcidin. Except in absolute iron deficiency, hepcidin’s negative association with Hb level indicates that it is not down-
regulated in CKD anemia.
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Introduction
Hepcidin is a new iron marker, discovered in 2001 and studied
especially in hemochromatosis. The first investigations concerned
prohepcidin, an inactive precursor. Prohepcidin has no impact on
iron metabolism in either healthy individuals [1] or patients with
chronic kidney disease (CKD) [2], [3]. The involvement of
hepcidin in iron disorders was clarified with the development of
methods to quantify hepcidin-25 [2], [4]. Hepcidin has been
evaluated in absolute iron deficiency, where its concentration is
low, and in patients with chronic disease-related anemia [5]. The
subsequent development of more specific assays for hepcidin-25
has led to a redefinition of normal values from around 50 ng/mL
for the first assays to less than 10 ng/mL for those recently
validated by the FDA [6]. Except in hemochromatosis, however,
hepcidin has not yet proved its usefulness in clinical practice.
Hepcidin involvement in CKD anemia has been explored in
both dialysis and non-dialysis CKD patients: both CKD-related
inflammation and lower hepcidin clearance tend to increase
hepcidin concentration in these patients [7], [8], [9]. The
specificity of hepcidin for the diagnosis of absolute iron deficiency
may thus be limited in this group. The hepcidin level does not
seem to improve the prediction of erythropoietin response [10],
[11]. Furthermore, its close relation with ferritin raises questions
about its performance in the diagnosis of iron disturbances [12]. In
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hemodialysis patients, its performance is no better than that of
traditional iron markers [2], [12]. Nonetheless, a better under-
standing of the determinants of hepcidin levels is essential to assess
its usefulness in CKD anemia. We therefore studied the
determinants of hepcidin in non-dialysis CKD patients, particu-
larly its relation to iron disorders, inflammation, and glomerular
filtration rate measured (mGFR) by a reference method. We also
tested the hypothesis that hepcidin and hemoglobin (Hb) levels are
related, independently of other Hb determinants.
Methods
Population
The NephroTest study is a prospective hospital-based cohort
that has enrolled patients with any diagnosis of CKD stages 1
through 5, recruited from three nephrology departments. Patients
younger than 18 years, dialysis patient or with a kidney transplant,
and pregnant women were excluded. Between January 2000 and
January 2012, NephroTest included 1095 patients after they had
provided written informed consent. The NephroTest study design
was approved by the relevant ethics committee (Direction
Ge´ne´rale pour la Recherche et l’Information, Comite´ Consultatif
sur le Traitement de l’Information en matie`re de Recherche dans
le domaine de la Sante´ MG/CP09.503) and adheres to the
Declaration of Helsinki. Patients not receiving EPO and intrave-
nous iron were included in this analysis if a plasma sample was
available for them. More precisely, 114 men were drawn from the
NEPHROTEST cohort samples from 2000 to 2004 and all
women of the same period were included (n= 48). Additionally, 37
women with plasma samples available from the 2006 to 2008
period were added to obtain a study population that was balanced
with respect to sex. Hepcidin was measured for these 199 patients.
They were similar to the overall study population with respect to
age and mGFR distribution (Appendix 1). Biopsy-proven
nephropathy was identified in 21% of all patients, but fewer than
10% of those with diabetes. Clinical criteria based on a history of
urinary albumin .300 mg/g creatinine and of other microangi-
opathy damage (retinopathy or neuropathy) were used to classify
diabetes patients who had not had renal biopsies with diabetic
glomerular nephropathy. Other diabetes patients were classified
with another nephropathy type, most probably vascular.
Laboratory measurements
Patients undergo an extensive annual check-up, including a
measurement of their GFR (mGFR) by *Cr-EDTA, in the
hospitals’ physiology departments [13]. Serum iron (DxC800
Beckman-Coulter, ferrozine, emitted light 560 nm), ferritin (BN-
Siemens, N-latex ferritin immunonephelometry), and transferrin
(BN-Siemens, N Antiserum antitransferrin immunonephelometry)
were measured. TIBC (total iron binding capacity, mmol/L) was
calculated as 256transferrin (g/L) and TSAT (%) as serum
iron6100/TIBC. Firstly, we used Lipschitz’s iron index [13] to
define iron status based on TSAT and ferritin together as follows:
normal, TSAT$20%; absolute iron deficiency, TSAT,20% and
ferritin ,40 ng/mL; functional iron deficiency, TSAT ,20% and
ferritin $40 ng/mL. The 40 ng/mL threshold value was chosen
for ferritin because this threshold is usually recommended to
diagnose absolute iron deficiency, in contrast with the KDIGO
threshold of 100 ng/mL used to define the need for iron supply in
patients with non-dialysis chronic kidney disease. Secondarily, we
used a combined iron marker containing 4 classes, built like the
Lipschitz iron index but separating TSAT $20% and ferritin $
40 ng/mL from TSAT $20% and ferritin ,40 ng/mL. Endog-
enous EPO levels were determined in serum (100 mL) with the
Quantitine IVD Epo double-antibody sandwich ELISA method
from R&D Systems (Minneapolis, MN), as reported elsewhere
[14]. EPO measurements were missing for 38 patients (37 women
and 1 men).
The assay for the quantification of hepcidin in human serum
was developed at Amgen, Thousand Oaks, CA, and is described in
appendix 2. Briefly, this immunoassay is based on hepcidin
capture by an anti-human hepcidin monoclonal antibody,
followed by electrochemiluminescent detection of the complex.
The normal reference level of hepcidin in healthy volunteers was
,10 ng/mL. The lower limit of detection was 0.1 ng/mL.
Statistical analyses
We studied crude and mGFR-adjusted relations of hepcidin
with age, gender, ethnicity, diabetes and diabetic nephropathy,
body mass index (BMI), mGFR, the urinary protein to creatinine
ratio (PCR), albuminemia, C-reactive protein (CRP), oral iron
treatment, erythropoietin, ferritin, TSAT, TIBC, and the com-
bined iron marker; we used ANOVA to compare categorial
variables and Pearson’s correlations for quantitative variables. The
hepcidin determinants were then analysed by multivariate
regression analysis that included age, gender, center, albumin,
BMI, CRP, mGFR, EPO, oral iron therapy, and the combined
iron marker. Finally, we tested the association of Hb levels with the
hepcidin concentration treated continuously after adjustment for
other Hb determinants. These included the combined iron marker
(or ferritin), gender, diabetes, BMI, mGFR, oral iron treatment,
albuminemia, CRP, and angiotensin converting enzyme inhibi-
tors/angiotensin receptor blockers. Potential interactions between
hepcidin and the combined iron marker (or ferritin) in the relation
with Hb were also tested. In all analyses, hepcidin was transformed
by its square root to meet the criterion of a normal parameter.
For covariates with less than 3% missing observations (albumin
and CRP), the median value was imputed in the multivariate
analysis. A missing data category was created for the combined
iron marker and EPO. Statistical analyses were performed with
SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and R 2.15 (R
Foundation for Statistical Computing, Vienna, Austria, 2012).
Results
Patients’ characteristics
Patients’ characteristics are shown in Table 1. Hepcidin ranged
from 0.2 to 193 ng/mL with a median value of 27.9 ng/mL [IQR
16.5–45.4]. According to Lipschitz’s iron index [15], 72.4% had
normal iron profiles, 6.3% absolute iron deficiency and 21.4%
functional iron deficiency. This distribution was similar to that
observed in the entire cohort (71.3%, 6.2%, and 18.6%). The
median mGFR for each class of the combined iron marker was
34.7 mL/min/1.73 m2 [IQR 24.0–48.3], 37.2 mL/min/1.73 m2
[24.8–56.0], and 36.0 mL/min/1.73 m2 [26.3–49.5].
Factors associated with hepcidin levels
Women younger than 55 years had lower hepcidin values than
either men or older women (Table 2). Hepcidin levels increased
from 23.3 ng/mL IQR [8.8–28.7] to 36.1 ng/mL IQR [14.1–
92.3] when mGFR declined from .60 mL/min/1.73 m2 to ,
15 mL/min/1.73 m2. Independent of mGFR, higher levels of
body mass index, albuminemia, C-reactive protein (CRP), oral
iron therapy and lower levels of proteinuria and EPO were
significantly associated with higher hepcidin concentrations
(Tables 2 and 3). Hepcidin levels were strongly related to all iron
markers and particularly to ferritin (Table 3 and Figure 1). The
hepcidin level varied in the different combined classes of TSAT
Hepcidin in Chronic Kidney Disease
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and ferritin (Table 4). It was six times lower in patients with
absolute iron deficiency and three times in those with low ferritin
alone than in those with normal iron status. The multivariate
analysis showed that oral iron therapy, albuminemia, EPO levels,
BMI $ 30 kg/m2 and mGFR all remained significantly associated
with hepcidin levels. The four-class iron index produced the model
with the best fit (Table 5). There was an interaction between iron
status profile and CRP in their relation with hepcidin (p = 0.01).
Patients with inflammation and either a functional or normal iron
profile had higher hepcidin levels than their counterparts without
inflammation (Table 5). Patients with ferritin ,40 ng/mL had an
hepcidin collapse.
Relation between Hb and hepcidin levels
There was a significant interaction with the four-class iron index
in the relation between hepcidin and Hb (p = 0.003). Hb levels
tended to decrease as hepcidin levels increased when TSAT ,
20% and ferritin .40 mg/L (Hb=20.1460.08, p= 0.06), but the
relation was reversed in patients with absolute iron deficiency,
defined by TSAT,20% and ferritin,40 mg/L (Hb= 0.3060.14,
p = 0.04). These relations were not modified when the four-class
iron index was combined with inflammation (data not shown).
Using ferritin instead of the combined iron marker produced
similar results for the relation between hepcidin and Hb, with
significant interaction between tertiles of ferritin and hepcidin (p,
0.001). Hb levels decreased significantly with increasing hepcidin
Table 1. Patient characteristics.
Mean ± SD, median (IQR) or %(N)
Men 57.3 (114)
Age, years 58.4614.8
African origin 5.8 (11)
Body mass index, kg/m2 25.565.0
Systolic/Diastolic Blood Pressure, mmHg 138620/76611
Diabetes
No 76.4 (152)
Yes, with diabetic nephropathy 15.1 (30)
Yes, with other nephropathy type 8.5 (17)
History of cardiovascular disease 12.6 (25)
mGFR, ml/min/1.73 m2 35.3 (24.2–49.3)
,15 7.0 (14)
15–30 28.1 (56)
30–45 33.7 (67)
45–60 18.1 (36)
.60 13.1 (26)
eGFR MDRD, ml/min/1.73 m2 33.3 (22.6–45.9)
eGFR CKD-EPI, ml/min/1.73 m2 34.2 (23.2–48.4)
PCR, mg/mmol 28.9 (15.3–115.1)
Serum albumin, g/L 39.5365.18
C-reactive protein .8 mg/L 11.0 (21)
Hb, g/dL 12.3261.47
WHO Anemia 54.8 (109)
Serum Iron, mmol/L 14.0665.16
Total iron binding capacity (TIBC), mmol/L 56.5610.9
Transferrin saturation (TSAT), % 25.4769.83
Ferritin, ug/L 110 (63–201)
Folates, ng/L 6.8 (5.0–9.5)
Vitamin B12, pg/mL 418 (291–558)
ACEi or ARB % 68.3 (136)
Oral iron therapy 11.1 (22)
Lipschitz’s iron index
TSAT $20% 72.4 (139)
TSAT ,20% and ferritin ,40 6.3 (12)
TSAT ,20% and ferritin $40 21.4 (41)
PCR: urinary protein to creatinine ratio; ACEi/ARBs: angiotensin converting enzyme inhibitors/angiotensin receptor blockers. WHO anemia: Hb ,13 g/dL for men and ,
12 g/dL for women.
doi:10.1371/journal.pone.0099781.t001
Hepcidin in Chronic Kidney Disease
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at intermediate (74–167 ng/mL, Hb=20.2260.09, p = 0.02) and
high ferritin values (.167 ng/mL, Hb=20.2060.08, p = 0.01),
and increased with hepcidin at low ferritin values (,74 ng/mL,
Hb= 0.1560.07, p = 0.04). Further adjustment for the EPO level
did not change the association of Hb and hepcidin (data not
shown).
Discussion
This study identified several factors other than mGFR that may
determine hepcidin levels in CKD patients. The most original
finding is our showing that even though hepcidin levels generally
increase as mGFR declines, CKD patients with absolute iron
deficiency still experienced a profound hepcidin collapse, in
contrast to those with other iron profiles. We also confirmed the
observation of an interaction between iron status and hepcidin in
their relation to Hb levels. These findings are especially
noteworthy because they are based on a patient population
carefully phenotyped for mGFR and a specific and accurate
hepcidin-25 assay with a low limit of detection.
Hepcidin is influenced by four regulation processes: hypoxia
[16], erythropoiesis, inflammation, and iron status. We confirmed
the main determinant factors of hepcidin seen in the general
population [17] and in the hemodialysis population [18], [19],
[20]. EPO deficiency and the chronic inflammation observed in
CKD patients play a role in the hepcidin increase. BMI was a
determinant of hepcidin, independently of inflammation. Some
hepcidin secretion is located in and directly related to the adipose
Table 2. Hepcidin level according to categorial factors.
N
Hepcidin (ng/mL)
Median (IQR) p-value
mGFR adjusted
p-value
Age6Gender Men 114 27.7 (19.0–43.1) 0.009 0.003
Women ,55 yrs 35 15.6 (8.8–40.2)
Women $55 yrs 50 34.6 (21.3–57.4)
Origin African 11 34.5 (8.0–63.9) 0.6 0.5
Caucasian or other 180 27.7 (16.6–43.6)
missing 8 47.6 (16.2–66.0)
Diabetes No 152 28.8 (17.7–46.1) 0.8 0.8
Yes with diabetic nephropathy 30 26.2 (12.5–45.2)
Yes with other
nephropathy type
17 21.4 (16.3–42.4)
Oral Iron Therapy No 177 27.1 (16.0–42.3) 0.005 0.01
Yes 22 46.5 (19.0–75.9)
ACEI/ARBs No 63 26.5 (16.0–48.3) 0.8 0.8
Yes 136 29.3 (17.2–44.7)
CRP #8 mg/L 170 26.7 (16.4–40.4) 0.0002 0.0005
.8 21 56.4 (26.1–73.2)
missing 8 23.8 (7.7–87.7)
CRP: C reactive protein; ACE/ARBs: angiotensin converting enzyme inhibitors/angiotensin receptor blockers.
doi:10.1371/journal.pone.0099781.t002
Table 3. Crude and mGFR-adjusted Pearson’s correlations of square root-transformed hepcidin with quantitative factors.
Crude correlation mGFR-adjusted partial correlation
r p-value r p-value
mGFR 20.31 ,.0001 - -
BMI 0.21 0.003 0.16 0.03
LOG PCR 0.01 0.9 20.18 0.01
Albuminemia 0.04 0.6 0.17 0.02
Free iron 0.05 0.5 0.18 0.01
TIBC 20.32 ,.0001 20.22 0.002
TSAT 0.15 0.04 0.24 0.0008
LOG Ferritin 0.62 ,.0001 0.71 ,.0001
LOG EPO 20.20 0.01 20.18 0.03
mGFR: measured glomerular filtration rate; BMI: body mass index; PCR: urinary protein to creatinine ratio; CRP: C-reactive protein; EPO: erythropoietin; TIBC: total iron
binding capacity; TSAT: transferrin saturation.
doi:10.1371/journal.pone.0099781.t003
Hepcidin in Chronic Kidney Disease
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tissue [21]. Finally, iron status influences hepcidin levels. A low
iron store down-regulates hepcidin, in a relation modulated by
transferrin [22], [23]. Our 3-marker iron index with five classes
produced similar results in this analysis (data not shown) [24]. In
our cohort, the combined iron marker we used to classify the
different iron profiles sheds light on the persistent process of
hepcidin down-regulation in absolute iron deficiency at the same
time that the patients with all other iron profiles had increasing
hepcidin levels associated with mGFR decline. This persistent
down-regulation has also been shown in animal models of chronic
disease anemia [5]. The down-regulation process remains effective
in and specific to absolute iron deficiency in CKD patients. The
possibility of defining a hepcidin threshold value for this diagnosis
requires further validation in CKD cohorts.
The influence of mGFR on hepcidin has been interpreted in
different ways in recent articles reporting the role of the hepcidin
assay. Hepcidin measurement is based on either mass spectrom-
etry or antibody-based hepcidin detection. Competitive radioim-
munoassays and ELISA tests have been developed for the
antibody-based methods. Several studies have reported that
hepcidin increases as mGFR declines [4], [17], [25]. The hepcidin
measurements in these articles, however, were performed with a
radioimmunoassay that might have cross-reacted with the isoform
hepcidin-20 for about 10% of the total measured value of
hepcidin-25. Further contestation of the relation between mGFR
and hepcidin has been based on suspicion that this relation is
restricted to hepcidin-20, which is inactive [26]. A large cohort
study of 505 CKD patients that used a highly specific liquid
chromatography tandem mass-spectrometry method found that
estimated GFR was associated with hepcidin levels in the
univariate but not the multivariate analysis [27]. Finally, from a
physiological point of view, the isoform hepcidin-25, the active
form, is a small peptide, freely filtered by the glomerulus and
highly reabsorbed by the proximal tubules with an excretion
fraction around 8%; it shares the renal clearance characteristics of
b2 microglobulin [28], [29]. A major strength of our study is the
use of 51Cr-EDTA renal clearance to determine GFR, which
reduced measurement errors and improved our ability to
understand the relation between renal function and hepcidin
level. It is likely that levels of the serum isoform hepcidin-25
increase with declining renal function, but the relation between
mGFR and hepcidin may have been disrupted by patients with
absolute iron deficiency because of their down-regulated hepcidin
level. Besides the difference in methods, differences in study
populations could have influenced the relation between hepcidin
and mGFR in some studies.
Anemia in CKD cohorts has been associated with elevated
hepcidin levels. This association reflects the ratios of the
prevalence rates of the different iron disturbances: absolute ID,
which depresses hepcidin, is relatively rare in CKD cohorts such as
Table 4. Hepcidin levels (ng/mL) and percentage of patients with low hepcidin values according to ferritin and transferrin
saturation (TSAT) levels.
Ferritin
$40 ng/mL ,40 ng/mL Total
TSAT $20% 34.5 (23.7–51.6)2
10% (12) N= 123
10.3 (6.9–14.1)2
80% (12) N = 15
31.2 (20.9–45.7)1
17% (24) N= 138
,20% 22.6 (16.3–43.1)1,2
29% (12) N= 41
5.0 (0.7–11.7)1,2
92% (11) N = 12
19.2 (12.2–40.3)
43% (23) N= 53
Total 32.1 (21.35–51.3)
15% (24) N= 164
9.6 (3.8–12.7)
85%(23) N = 27
Median (Interquartile range).
% (N) of patients with hepcidin values below a threshold value of hepcidin defined as the 10th percentile of patients with normal iron profile (16.7 ng/mL).
1Three classes of Lipschitz’s iron index.
2Four classes iron index.
doi:10.1371/journal.pone.0099781.t004
Figure 1. Hepcidin concentration according to quintiles of ferritin (A), transferrin saturation (B) and total iron-binding capacity (C).
doi:10.1371/journal.pone.0099781.g001
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ours (6.3%). Functional iron deficiency is more frequent and is
associated with an elevated hepcidin level. Our functional iron
profile group had elevated hepcidin levels, similar to those of the
normal iron profile group. Combining a functional iron deficiency
and overt inflammation further increased hepcidin in our study.
The short half-life of hepcidin (22 hours), its high intra-patient
variability, and the cross-sectional design of our study might have
weakened the link between functional iron deficiency and a
hepcidin increase. Recently in a mouse model, the hepcidin
increase has been proved to be limited to the early phase of the
inflammation process [30].
We confirmed that the relation between Hb and hepcidin varies
according to iron status. In the study by Uehata et al [27],
hepcidin was not related to Hb in the low ferritin group (,91 ng/
mL) and was negatively related to it in the high ferritin group. The
low ferritin group probably had absolute iron deficiency, with a
very low hepcidin level of 7 ng/mL (IQR 2.3–17.3 ng/mL, with
liquid chromatography mass spectrometry). We showed that in the
absolute iron deficiency group, Hb decreased with hepcidin. On
the contrary, in patients with functional iron deficiency, anemia
was related to an increased hepcidin level. The hepcidin level thus
provides information about Hb above and beyond that contained
in the iron profiles. Elevated hepcidin can predict poor gut
absorption of iron and ineffective oral iron treatment. In vitro
studies suggest that hepcidin has a direct effect on erythropoiesis
by inhibiting erythroid colony formation when erythropoietin is
low and by impairing red blood cell survival. To date, however, no
study has found that hepcidin has any predictive value for response
to either IV iron or ESA.
The limitations of our study are linked mainly to its cross-
sectional design, its sample size, and the measurement method.
The cross-sectional design makes it difficult to infer causality
between the hepcidin level and the risk of anemia. In terms of
sample size among non-dialysis CKD cohorts, our study is the
second largest examining hepcidin levels, after that of Uehata et al
[27]. The immunochemical method that we used measured
hepcidin levels in patients with absolute iron deficiency similar to
those in the study of Uehata et al, which used mass spectrometry.
The antibody-based hepcidin assays may diagnose and discrim-
inate absolute iron deficiency quite well. On the contrary, when
hepcidin values are elevated, the lower specificity for hepcidin-25
of the immunochemical test we used might have impaired its
power to discriminate patients with normal iron profile from those
with functional iron deficiency profile.
In conclusion, this study primarily shows the importance of
considering iron profiles in improving our understanding of the
changes of the hepcidin concentration as renal function declines as
well as its association with CKD anemia. While absolute iron
deficiency is associated with a profound hepcidin collapse
independently of the GFR decline, hepcidin is elevated in all
other CKD patients and thus impairs the oral iron absorption in
these patients. These findings have prompted research on drug
development focusing on a hepcidin antagonist in CKD and
possibly other chronic disease anemia with functional iron
Table 5. Multivariate analyses of hepcidin levels according to different definitions of iron status.
N BIC/AIC
!hepcidin
b±sd p-value
Lipschitz’s iron index1,2 877/821
TSAT $20% 139 ref
TSAT ,20% and Ferritin ,40 mg/L 12 22.7160.55 ,.0001
TSAT ,20% and Ferritin $40 mg/L 41 20.3260.32 0.3
Missing 7 20.0460.71 0.9
Four classes iron index1,2 848/788
TSAT $20% and Ferritin $40 mg/L 123 ref
TSAT $20% and Ferritin ,40 mg/L 15 22.8460.46 ,.0001
TSAT ,20% and Ferritin ,40 mg/L 12 23.2560.51 ,.0001
TSAT ,20% and Ferritin $40 mg/L 41 20.6560.30 0.03
Missing 8 20.1660.61 0.8
Four classes iron index according to CRP levels1 848/785
TSAT $20%, Ferritin $40 mg/L
CRP #8 ng/mL 115 ref
CRP .8 ng/mL 8 1.8760.61 0.002
TSAT $20% and Ferritin ,40 mg/L 15 22.5460.46 ,.0001
TSAT ,20% and Ferritin ,40 mg/L 12 23.0960.51 ,.0001
TSAT ,20%, Ferritin $40 mg/L
CRP #8 ng/mL 32 20.9060.32 0.005
CRP .8 ng/mL 9 2.3360.57 ,.0001
Missing 8 0.0660.60 0.9
Abbreviations: TSAT, Transferrin saturation; CRP, C-reactive protein; BIC, Bayesian Information Criterion; AIC, Akaike information Criterion; Ref, reference class.
b±sd Regression coefficients for the different iron indexes in the linear regression models of hepcidin values (square-root transformed).
1Models were adjusted for measured glomerular filtration rate, gender, age, body mass index, albuminemia, erythropoietin, oral iron and centre.
2Models for Lipschitz’s iron index and the four-class iron index were also adjusted for C-reactive protein (CRP) in two classes (#8 vs .8 ng/mL).
doi:10.1371/journal.pone.0099781.t005
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deficiency, although the possible side effects of these drugs may
limit their potential.
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